Fig. 6

YAP1/TAZ overexpression impairs the promoting effect of metformin on osteoporotic fracture repair. a Schematic diagram of the experimental design for assessing the effects of metformin on fracture healing in the osteoporotic mice with YAP1/TAZ overexpression. b Representative μCT reconstruction images of fractured femora from the osteoporotic mice treated with the AAV control, Met, Met + Yap1/Taz-AAV, and Yap1/Taz-AAV at 6 weeks post-fracture. Met: metformin. Bar: 60 μm. c Quantitative analysis of the bone volume fraction (BV/TV) of calluses at 6 weeks post-osteoporotic fracture. n = 9 per group. d Three-point bending test of the femoral ultimate load at 6 weeks post-osteoporotic fracture. n = 5 per group. e Representative images of CD31, HIF-1α, YAP1, TAZ, and Ki67 coimmunostaining with Emcn in calluses from the osteoporotic mice at 6 weeks post-fracture (left) and their quantification analysis (right). ca: callus. The dotted line represents the boundary of the callus. Scale bar: 100 μm. n = 5 per group. Data are presented as the mean ± SEM. ^*P < 0.05, ^**P < 0.01, and ^***P < 0.001